Progress of chimeric antigen receptor T-cell in treatment of lymphoma / 白血病·淋巴瘤

ABSTRACT

Chimeric antigen receptor T-cell (CAR-T) has changed the treatment landscape of lymphoma. Plenty of research progresses have been made at 63rd annual meeting of American Society of Hematology. Studies with long-term follow-up indicated that CD19 CAR-T is expected to cure 30%-40% of relapsed or refractory large B-cell lymphoma (LBCL). A few studies indicated that CD19 CAR-T would be applied in the second-line or first-line therapy for LBCL. Real world studies further confirmed the efficacy and safety of CD19 CAR-T in treatment of relapsed or refractory follicular lymphoma and mantle cell lymphoma. CAR-T therapy has a promising prospect in the cinical application.